Population Pharmacokinetics and Exposure-Response Analyses of an MDM2 Inhibitor Milademetan

被引：0

作者：

Kang, Dongwoo ^{[1
]}

Kumar, Prasanna ^{[1
]}

Zernovak, Oleg ^{[1
]}

Song, Saeheum ^{[1
]}

Xiong, Yuan ^{[2
]}

Bergsma, Tim ^{[2
]}

Lovern, Mark ^{[2
]}

Yin, Ophelia ^{[1
]}

机构：

[1] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[2] Certara, Princeton, NJ USA

来源：

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2018年 / 45卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

M-045

引用

下载

页码：S24 / S24

页数：1

共 50 条

[21] Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer
Nguyen, Jenny-Hoa
Epling, Daniel
Dolphin, Nancy
Paccaly, Anne
Conrado, Daniela
Davis, John D.
Al-Huniti, Nidal
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (11): : 1458 - 1471
[22] A phase 2 basket study of the oral MDM2 inhibitor milademetan for MDM2-amplified advanced solid tumors (MANTRA-2)
Dumbrava, Ecaterina E.
Chen, Christopher T.
Cote, Gregory M.
Hanna, Glenn J.
Stinchcombe, Thomas E.
Sumrall, Bradley
Wise-Draper, Trisha
Kanaan, Mohammed
Duffy, Steven
Sumey, Christopher
Cobb, Patrick
Shah, Naisargee
Zhang, Bo
Ku, Nora
Doebele, Robert C.
Gounder, Mrinal
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[23] Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Koyama, Takafumi
Shimizu, Toshio
Kojima, Yuki
Sudo, Kazuki
Okuma, Hitomi Sumiyoshi
Shimoi, Tatsunori
Ichikawa, Hitoshi
Kohsaka, Shinji
Sadachi, Ryo
Hirakawa, Akihiro
Yoshida, Akihiko
Ando, Reiko Makihara
Ueno, Toshihide
Yanagaki, Mitsuru
Matsui, Naoko
Nakamura, Kenichi
Yamamoto, Noboru
Yonemori, Kan
CANCER DISCOVERY, 2023, 13 (08) : 1814 - 1825
[24] Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation
Kovarik, JM
Kahan, BD
Rajagopalan, PR
Bennett, W
Mulloy, LL
Gerbeau, C
Hall, ML
TRANSPLANTATION, 1999, 68 (09) : 1288 - 1294
[25] Pharmacokinetics, Pharmacodynamics and Exposure-Response Analyses of Ocrelizumab in Patients With Multiple Sclerosis
Kletzl, Heidemarie
Gibiansky, Ekaterina
Petry, Claire
Mercier, Francois
Guenther, Andreas
Wang, Qing
Model, Fabian
Kappos, Ludwig
Hauser, Stephen
NEUROLOGY, 2019, 92 (15)
[26] Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis
Xu, Yan
Hu, Chuanpu
Chen, Yang
Miao, Xin
Adedokun, Omoniyi J.
Xu, Zhenhua
Sharma, Amarnath
Zhou, Honghui
JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07): : 889 - 902
[27] Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
Adedokun, Omoniyi J.
Xu, Zhenhua
Gasink, Christopher
Kowalski, Ken
Sandborn, William J.
Feagan, Brian
CLINICAL THERAPEUTICS, 2022, 44 (10) : 1336 - 1355
[28] Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
Dosne, Anne-Gaelle
Li, Xia
Luo, Man Melody
Nnane, Ivo
Dimopoulos, Meletios A.
Terpos, Evangelos
Sonneveld, Pieter
Kampfenkel, Tobias
Carson, Robin
Amin, Himal
Ruixo, Juan Perez
Zhou, Honghui
Sun, Yu-Nien
Xu, Yan
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (05) : 1640 - 1655
[29] Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis
Xu, Yan
Adedokun, Omoniyi J.
Chan, Daphne
Hu, Chuanpu
Xu, Zhenhua
Strauss, Richard S.
Hyams, Jeffrey S.
Turner, Dan
Zhou, Honghui
JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (04): : 590 - 604
[30] POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES TO INFORM DOSING OF ICATIBANT IN PEDIATRIC PATIENTS WITH HEREDITARY ANGIOEDEMA.
Wang, Y.
Jomphe, C.
Marier, J.
Martin, P.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S95 - S96

← 1 2 3 4 5 →